Somewhat Favorable Media Coverage Somewhat Unlikely to Impact Nevro Corp. (NYSE:NVRO) Share Price

Headlines about Nevro Corp. (NYSE:NVRO) have trended somewhat positive on Saturday, Accern Sentiment reports. The research firm ranks the sentiment of news coverage by analyzing more than twenty million news and blog sources in real time. Accern ranks coverage of publicly-traded companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Nevro Corp. earned a daily sentiment score of 0.17 on Accern’s scale. Accern also gave media coverage about the medical equipment provider an impact score of 46.3672869572822 out of 100, indicating that recent news coverage is somewhat unlikely to have an impact on the stock’s share price in the immediate future.

These are some of the headlines that may have effected Accern’s rankings:

NVRO has been the subject of a number of research analyst reports. B. Riley downgraded shares of Nevro Corp. from a “buy” rating to a “neutral” rating and dropped their target price for the stock from $108.00 to $85.00 in a research note on Tuesday, May 9th. Morgan Stanley lifted their price target on shares of Nevro Corp. from $87.00 to $95.00 and gave the stock an “overweight” rating in a research report on Tuesday. Zacks Investment Research cut shares of Nevro Corp. from a “hold” rating to a “sell” rating in a research report on Thursday, May 11th. ValuEngine cut shares of Nevro Corp. from a “hold” rating to a “sell” rating in a research report on Wednesday, May 24th. Finally, BidaskClub cut shares of Nevro Corp. from a “hold” rating to a “sell” rating in a research report on Friday, July 28th. Two research analysts have rated the stock with a sell rating, two have assigned a hold rating and five have issued a buy rating to the stock. The company presently has an average rating of “Hold” and an average price target of $100.57.

Shares of Nevro Corp. (NYSE NVRO) traded up 1.27% during midday trading on Friday, hitting $81.90. 303,020 shares of the stock traded hands. The company’s market capitalization is $2.41 billion. Nevro Corp. has a 52 week low of $65.82 and a 52 week high of $106.93. The firm’s 50-day moving average is $82.27 and its 200 day moving average is $85.24.

Nevro Corp. (NYSE:NVRO) last issued its quarterly earnings data on Monday, August 7th. The medical equipment provider reported ($0.40) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.29) by $0.11. The business had revenue of $78.02 million during the quarter, compared to the consensus estimate of $77.75 million. Nevro Corp. had a negative net margin of 14.33% and a negative return on equity of 16.25%. The firm’s quarterly revenue was up 40.8% compared to the same quarter last year. During the same quarter last year, the business earned ($0.31) EPS. Equities analysts forecast that Nevro Corp. will post ($1.17) earnings per share for the current year.

In related news, CFO Andrew H. Galligan sold 7,500 shares of the firm’s stock in a transaction that occurred on Monday, May 15th. The shares were sold at an average price of $75.30, for a total value of $564,750.00. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. 12.10% of the stock is owned by company insiders.

ILLEGAL ACTIVITY WARNING: “Somewhat Favorable Media Coverage Somewhat Unlikely to Impact Nevro Corp. (NYSE:NVRO) Share Price” was posted by StockNewsTimes and is the property of of StockNewsTimes. If you are reading this article on another domain, it was illegally copied and republished in violation of U.S. & international copyright laws. The legal version of this article can be accessed at https://stocknewstimes.com/2017/08/12/somewhat-favorable-media-coverage-somewhat-unlikely-to-impact-nevro-corp-nysenvro-share-price.html.

About Nevro Corp.

Nevro Corp. is a global medical device company. The Company focuses on providing products that improve the quality of life of patients suffering from chronic pain. The Company has developed and commercialized the Senza spinal cord stimulation (SCS) system, an evidence-based neuromodulation platform for the treatment of chronic pain.

Insider Buying and Selling by Quarter for Nevro Corp. (NYSE:NVRO)

Receive News & Ratings for Nevro Corp. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nevro Corp. and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply